BE study design issue [Design Issues]

posted by Dr_Dan  – 2019-12-18 15:04 (285 d 01:21 ago) – Posting: # 20992
Views: 1,685

Hi John
if the recommended dosage regimen of the IR as per product monograph IR is to be given every 4 hrs then this means that higher doses have either a safety issue or the dose/effect relationship is in disfavor of higher doses. In this case AUC alone does not matter. Consequently, a regulatory body will reject the study
Hope this helps

Kind regards and have a nice day

Complete thread:

 Admin contact
21,083 posts in 4,398 threads, 1,468 registered users;
online 7 (1 registered, 6 guests [including 2 identified bots]).
Forum time: Monday 17:26 CEST (Europe/Vienna)

A central lesson of science is that to understand complex issues
(or even simple ones), we must try to free our minds of dogma and
to guarantee the freedom to publish, to contradict, and to experiment.
Arguments from authority are unacceptable.    Carl Sagan

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz